Author details
Author Christa Harstall |
Available item(s) by this author (2)
Add the result to your basket Make a suggestion Refine your search Apply to external sourcesCelecoxib for the Treatment of Pain in Osteoarthritis and Rheumatoid Arthritis / Carmen Moga / Alberta [Canada] : Institute of Health Economics (2005)
ISSN : 1-894827-12-5 : 0 €
Languages : English (eng)
Descriptors: Indexation
Anti-Inflammatory Agents, Non-Steroidal ; Arthritis, Rheumatoid ; drug therapy ; Therapeutics
Classification
WB 330 Drug therapyAbstract: Overall, short-term use of celecoxib was equivalent to non-selective NSAIDs (naproxen and diclofenac) and other COX-2 inhibitors (nimesulide and rofecoxib) and was superior to acetaminophen in reducing pain and improving function for patients with RA and OA. Short-term use of celecoxib was associated with a reduction in rates of gastroduodenal erosions or ulcers compared with those for non-selective NSAIDs (naproxen, ibuprofen, and diclofenac) in patients with RA and OA. Many questions remain to be addressed about the long-term safety of celecoxib compared with non-selective NSAIDs and about the combination treatment of NSAIDs and other types of drugs. Health Canada recommended usage restrictions for Celebrex beginning in April 2005. Celebrex should not be used in patients who have had a heart attack or stroke, serious chest pain related to hearth disease, or congestive heart failure. Celebrex may increase the risk of cardiovascular events in patients with high blood pressure, high cholesterol, diabetes, and smoking. Also, Celebrex should be prescribed and used at the lowest possible dose and for the shortest, necessary period of time. Contents note: ACKNOWLEDGEMENTS . I -- EXECUTIVE SUMMARY . III -- ABBREVIATIONS . V -- SCOPE .1 -- BACKGROUND.2 -- EPIDEMIOLOGICAL AND CLINICAL ASPECTS .3 -- COX-2 INHIBITORS .4 -- EVIDENCE FROM SRS .6 -- Efficacy/effectiveness .8 -- Safety ..8 -- EVIDENCE FROM RCTS .12 -- Efficacy/effectiveness .16 -- Safety .17 -- REGULATION STATUS AND POST-MARKETING DATA.20 -- Health Canada and FDA regulatory status .20 -- Labeling and public health alerts in the United States, Canada, and Australia .21 -- Post-marketing data in Canada .22 -- POSITION PAPERS AND GUIDELINES .24 -- COST AND MARKETING .26 -- DISCUSSION .28 -- SRs on celecoxib .28 -- RCTs on celecoxib .28 -- Future research .29 -- Clinical relevance .30 -- CONCLUSION .33 -- REFERENCES .34 -- APPENDIX A: SEARCH AND METHODOLOGY .41 -- APPENDIX B.1: SYSTEMATIC REVIEWS ON EFFICACY/EFFECTIVENESS AND SAFETY .54 -- APPENDIX B.2: RCTS ON EFFICACY/EFFECTIVENESS AND SAFETY .58 -- APPENDIX C: STUDIES (RCTS) ON CELECOXIB FOR OA AND RA INCLUDED IN THE SYSTEMATIC REVIEWS .62 -- APPENDIX D: QUALITY ASSESSMENT CHECKLIST FOR SYSTEMATIC REVIEWS .66 -- APPENDIX E: EXCLUDED SYSTEMATIC REVIEWS AND RANDOMIZED CONTROLLED STUDIES .71 -- Tables and Figures -- FIGURE 1: NUMBER NEEDED TO HARM (NNH) .32 -- TABLE 1: CYCLO-OXYGENASE SELECTIVITY OF COX-2 SELECTIVE AND NON-SELECTIVE NSAIDS (IN VITRO DETERMINATIONS) .5 -- TABLE 2: SUMMARY OF SYSTEMATIC REVIEWS .7 -- TABLE 3: SUMMARY OF RCTS .13 -- TABLE 4: LICENSURE AND INDICATIONS IN CANADA AND THE UNITED STATES .20 -- TABLE 5: POSITION PAPERS AND GUIDELINES ON THE USE OF COX-2 INHIBITORS FOR RA AND OA .25 -- TABLE A.1: DATABASES AND SEARCH TERMS USED IN THE SEARCH STRATEGY (MARCH 2004) .42 -- TABLE A.2: DATABASES AND SEARCH TERMS USED IN THE UPDATED SEARCH STRATEGY (NOVEMBER 2004) .45 -- TABLE A.3: EFFICACY/EFFECTIVENESS OUTCOME MEASURES .51 -- TABLE A.4: SAFETY OUTCOME MEASURES .52 -- TABLE B.1.1: EFFICACY/EFFECTIVENESS OF CELECOXIB FOR THE TREATMENT OF RA .54 -- TABLE B.1.2: SAFETY OF CELECOXIB FOR THE TREATMENT OF OA AND RA .55 -- TABLE B.2.1: EFFICACY/EFFECTIVENESS AND SAFETY OF CELECOXIB FOR THE TREATMENT OF OA AND RA .58 -- TABLE C.1: STUDIES (RCTS) ON CELECOXIB FOR OA AND RA INCLUDED IN THE SYSTEMATIC REVIEWS .62 -- TABLE D.1: CRITICAL APPRAISAL OF REVIEWS .69 -- TABLE E.1: EXCLUDED SYSTEMATIC REVIEWS .71 -- TABLE E.2: EXCLUDED RANDOMIZED CONTROLLED STUDIES .72 Link for e-copy: http://www.ihe.ca/publications/library/archived/celecoxib-for-the-treatment-of-p [...] Format of e-copy: PDF (553 KB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1761 Copies(1)
Barcode Call number Media type Location Section Status 10273-01742 WB 330/MOG Report KCE Library (10.124) Not for loan
ISBN : 978-1-897443-57-6 : 0 €
This report on Exercise Testing for the Prediction of Cardiac Events in Patients with Diabetes examines the clinical research evidence on the prognostic value of exercise testing (including electrocardiogram exercise testing and cardiopulmonary exercise testing) for the prediction of cardiac events in patients with diabetes.
Languages : English (eng)
Descriptors: Classification
WK 810 Diabetes mellitus
Indexation
Canada ; Diabetes Mellitus ; Exercise Test ; Heart Diseases ; Prognosis ; Risk Factors ; Technology Assessment, BiomedicalContents note: EXECUTIVE SUMMARY IV -- ABBREVIATIONS VI -- GLOSSARY OF TERMS VII -- Introduction 10 -- Scope of the Report 10 -- Background 11 -- Clinical condition 11 -- Definition 11 -- Epidemiology 11 -- Prognosis 11 -- Management − physical exercise 12 -- Safety concerns about exercise 13 -- Pre-exercise examinations 13 -- Overvie w of Technology – Exercise Testing 14 -- Description of exercise testing 14 -- Exercise ECG test (graded exercise test) 14 -- Cardiopulmonary exercise testing (CPET) 15 -- Six-minute walking test (6MWT) 16 -- Indications and contraindications 17 -- Indications 17 -- Contraindications 17 -- Safety issues 18 -- Local Context 18 -- Methods of Analy zing Prognostic Studies 19 -- Definitions 19 -- Analytical methods and interpretation 19 -- Available Evidence 20 -- Description of the selected studies 20 -- Methodological quality of the selected studies 21 -- Prognostic value of exercise testing 22 -- ECG ST-segment deviation 25 -- Duke Treadmill Score 26 -- Delayed heart rate recovery 27 -- Metabolic equivalents (METs) 28 -- Peak VO2 28 -- Impaired chronotropic response (CR) 29 -- Safety 29 -- Guidelines/Consensus Statements /Position statement 30 -- Discussion 31 -- Summary of results 31 -- Methodological issues 32 -- Questions unanswered 32 -- Which patient groups can forgo the exercise stress testing? 33 -- The best way to predict patients’ risk of future cardiac events 34 -- Limitations 34 -- Conclusion 35 -- Appendix A: Method 36 -- Appendix B: Living Well Exercise Test Triage 45 -- Appendix C: Excluded Studies 48 -- Appendix D: Quality Assessment Results 52 -- Appendix E: Summary Of Results From The Selected Prognostic Studies 55 -- Appendix F: Covariates Considered In The Included Prognostic Studies 61 -- Appendix G: Patients With Chronic Diseases Who May Forego Exercise Testing 62 -- References 63 -- List of Tables and Figures -- Figure 1: Living well exercise test triage 46 -- Table 1: Contraindications to exercise testing 17 -- Table 2: Overview of the included prognostic studies 21 -- Table 3: Characteristics of the included participants 23 -- Table 4: Prognostic variables under investigation 24 -- Table A.1: Search strategy 36 -- Table C.1: Excluded studies and reasons for exclusion 48 -- Table D.1: Methodological quality assessment results 53 -- Table E.1: Prognostic studies for diabetes 55 -- Table F.1: Covariates considered in the univariate analysis 61 Link for e-copy: http://www.ihe.ca/documents/Exercise_Testing_Diabetes.pdf Format of e-copy: PDF (1,3 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1746 Hold
Place a hold on this item
Copies(1)
Barcode Call number Media type Location Section Status 10273-01733 WK 810 /GUO Book KCE Library (10.124) Available
